H.C. Wainwright analyst Raghuram Selvaraju upgraded Idorsia (IDRSF) to Buy from Neutral with a price target of CHF 6, up from CHF 2. The company’s guidance provided a pathway to profitability, driven by European and Canadian market uptake of its marketed anti-insomnia medication daridorexant, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDRSF: